Abundant evidence supporting the cancer promoting roles of PRL-PTP and other phosphatases in cancer immunotherapy.
These are one of the top untapped targets for anti-cancer therapy.
Currently no known activity on PRL inhibitor development or appllication in immunotherapy with anti-PTP inhibitor. Proprietary data on targeting PRL/CNNM complex and other PTPs provide head start on competition.
Kanyr will focus on the indication with the greatest probability for a positive
Kanyr was incorporated in May 2013.
Acquired rights from McGill for two major cancer programs:
PRL-PTP inhibitor and ImmunyrTM technology.
In the process of establishing seed funding.
Kanyr’s research team possesses >15 years of experience in the PTP field.
Is a “world-leader” in the understanding of how to chemically target PTP gene family.
PTP gene-family is associated with multiple human diseases but remains one of the few untapped areas of drug discovery.